0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-4 R alpha

IL-4 R alpha

Brief Information

Name:Interleukin-4 receptor subunit alpha
Target Synonym:IL-4R-alpha,Soluble IL-4 receptor subunit alpha,582J2.1,Soluble IL-4R-alpha,IL-4RA,IL4-BP,sIL4Ralpha/prot,CD124,Interleukin 4 Receptor,IL-4 Receptor Subunit Alpha,IL4RA,Interleukin-4 Receptor Subunit Alpha,Interleukin-4 Receptor Alpha Chain,IL4R Nirs Vari
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

ILR-H5253-ELISA
Human IL-4 R alpha, Fc TagHuman IL-4 R alpha, Fc Tag (Cat. No. ILR-H5253) ELISA bioactivity

Immobilized Human IL-4, Tag Free (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well)can bind Human IL-4 R alpha, Fc Tag (Cat. No. ILR-H5253) with a linear range of 1-20 ng/mL (QC tested).

ILR-H82F4-MALS-HPLC
Biotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ILR-H82F4) was more than 90% and the molecular weight of this protein is around 120-147 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human IL-4 R alpha, Fc,AvitagBiotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ILR-H82F4) ELISA bioactivity

Immobilized ActiveMax® Human IL-4, Tag Free (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ILR-H82F4) with a linear range of 0.5-16 ng/mL (QC tested).

Customer Reviews

Synonym Name

IL4R,CD124,IL4RA

Background

IL-4 is a pleiotropic cytokine produced by activated Th2 cells and mast cells, and plays a pivotal role in immune responses. The effects of IL-4 are mediated after binding to high affinity receptor complexes present on hematopoietic as well as non-hematopoietic cells. Hematopoietic cellular responses to IL-4 are mediated by a high affinity receptor complex comprised of the 140 kDa IL4Rα (CD124)subunit and the 70 kDa common cytokine γc chain (CD132).Interleukin 4 Receptor (IL4R) also known as CD124, IL4Rα and BSF receptor, is a  type I cytokine receptor produced by activated Th2 cells and mast cells, and plays an important role in Th2-­biased immune responses, alternative macrophage activation, mucosal immunity, allergic inflammation, tumor progression, and atherogenesis. A soluble form of the encoded IL4R protein can be produced by an alternate splice variant or by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. IL4R can alternatively associate with IL­13Ra1 to form the type II receptor which is responsive to both IL­4 and IL­13. Interleukin-4 receptor has been shown to interact with SHC1.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Dupilumab SAR-231893; REGN-668 Approved Sanofi, Regeneron Pharmaceuticals Inc Dupixent Mainland China Dermatitis, Atopic Sanofi-Aventis Group 2017-03-28 Pemphigoid, Bullous; Hypersensitivity; Dermatitis, Atopic; Keratoconjunctivitis; Peanut Hypersensitivity; Hypersensitivity, Immediate; Pulmonary Disease, Chronic Obstructive; Prurigo; Sinusitis; Urticaria; Aspergillosis, Allergic Bronchopulmonary; Neurodermatitis; Asthma; Rhinitis, Allergic; Eosinophilic Esophagitis; Genetic Diseases, Inborn; Skin Diseases; Skin Diseases, Eczematous; Dermatitis; Chronic Urticaria Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SHR-1819 SHR-1819 Phase 1 Clinical Atridia Pty Ltd Asthma Details
Interleukin-4(38-37)-PE38KDEL MDNA-55; IL4-PE; NBI-3001; PRX-321 Phase 2 Clinical Neurocrine Biosciences, National Institute of Health, Islamabad Kidney Neoplasms; Glioblastoma; Central Nervous System Neoplasms; Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Glioma Details
PRS-060 PRS-060; AZD-1402 Phase 2 Clinical University Of Melbourne, Pieris Pharmaceuticals Asthma Details
Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian) 611 Phase 2 Clinical Shanghai Cp Guojian Pharmaceutical Co Ltd Dermatitis, Atopic Details
Recombinant humannized monoclonal antibody (Conmed Biosciences) CM-310 Phase 2 Clinical CSPC Pharmaceutical Group Ltd, Connaught Biomedical Technology (Chengdu) Co Ltd Nasal Polyps; Sinusitis; Asthma; Dermatitis, Atopic Details
MG-K10 MG-K10; MG-010 Phase 1 Clinical Shanghai Mabgeek Biotechnology Co Ltd, Dragonboat Biopharmaceutical Asthma; Dermatitis, Atopic Details
QX-005N QX-005N Phase 2 Clinical Jiangsu Quanxin Biomedical Co Ltd Dermatitis, Atopic Details
CBP-201 CBP-201 Phase 2 Clinical Suzhou Conrad Biomedicine Co Ltd Nose Diseases; Nasal Polyps; Status Asthmaticus; Asthma; Sinusitis; Dermatitis, Atopic Details
AK120 (Akeso Biopharma) AK120 (Akeso Biopharma) Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Dermatitis, Atopic Details

This web search service is supported by Google Inc.

totop